Does the media prefer ACRS or CRBP?

In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.36 beat Corbus Pharmaceuticals' score of -0.10 indicating that Aclaris Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aclaris Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corbus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, CRBP or CADL?

Candel Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A

Is CRBP or CADL more profitable?

Candel Therapeutics' return on equity of -60.42% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% Candel Therapeutics N/A -60.42% -41.33%

Does the media favor CRBP or CADL?

In the previous week, Corbus Pharmaceuticals had 4 more articles in the media than Candel Therapeutics. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 2 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.00 beat Corbus Pharmaceuticals' score of -0.10 indicating that Candel Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corbus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TLRY or CRBP?

In the previous week, Tilray Brands had 14 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 20 mentions for Tilray Brands and 6 mentions for Corbus Pharmaceuticals. Tilray Brands' average media sentiment score of 0.68 beat Corbus Pharmaceuticals' score of -0.10 indicating that Tilray Brands is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tilray Brands 9 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corbus Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, CRBP or DRUG?

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Corbus Pharmaceuticals N/A N/A -$78.54M -$5.82 N/A Bright Minds Biosciences N/A N/A -$8.74M -$2.44 N/A

Is CRBP or DRUG more profitable?

Bright Minds Biosciences' return on equity of -20.58% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Corbus Pharmaceuticals N/A -70.89% -61.78% Bright Minds Biosciences N/A -20.58% -20.25%

Corbus Pharmaceuticals (CRBP) Competitors

$8.18 -0.28 (-3.31%)

Closing price 06/24/2026 04:00 PM Eastern

Extended Trading

$8.24 +0.05 (+0.67%)

As of 06:51 AM Eastern

Compare

CRBP vs. ACRS, CADL, TLRY, GYRE, and DRUG

Should you buy Corbus Pharmaceuticals stock or one of its competitors? MarketBeat compares Corbus Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corbus Pharmaceuticals include Aclaris Therapeutics (ACRS), Candel Therapeutics (CADL), Tilray Brands (TLRY), Gyre Therapeutics (GYRE), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry.

How does Corbus Pharmaceuticals compare to Aclaris Therapeutics?

Aclaris Therapeutics (NASDAQ:ACRS) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

98.3% of Aclaris Therapeutics shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 4.8% of Aclaris Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Corbus Pharmaceuticals has a net margin of 0.00% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

Aclaris Therapeutics currently has a consensus target price of $11.50, suggesting a potential upside of 140.08%. Corbus Pharmaceuticals has a consensus target price of $40.67, suggesting a potential upside of 397.15%. Given Corbus Pharmaceuticals' higher probable upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Aclaris Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclaris Therapeutics	$7.83M	85.44	-$64.92M	-$0.56	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

In the previous week, Corbus Pharmaceuticals had 3 more articles in the media than Aclaris Therapeutics. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 3 mentions for Aclaris Therapeutics. Aclaris Therapeutics' average media sentiment score of 0.36 beat Corbus Pharmaceuticals' score of -0.10 indicating that Aclaris Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aclaris Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corbus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aclaris Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.57, meaning that its stock price is 157% more volatile than the broader market.

Summary

Aclaris Therapeutics beats Corbus Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Candel Therapeutics?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Corbus Pharmaceuticals has a beta of 2.57, suggesting that its stock price is 157% more volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.49, suggesting that its stock price is 149% less volatile than the broader market.

Candel Therapeutics' return on equity of -60.42% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Candel Therapeutics	N/A	-60.42%	-41.33%

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Corbus Pharmaceuticals presently has a consensus target price of $40.67, suggesting a potential upside of 397.15%. Candel Therapeutics has a consensus target price of $18.00, suggesting a potential upside of 94.17%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Corbus Pharmaceuticals is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Candel Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

In the previous week, Corbus Pharmaceuticals had 4 more articles in the media than Candel Therapeutics. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 2 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.00 beat Corbus Pharmaceuticals' score of -0.10 indicating that Candel Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corbus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Corbus Pharmaceuticals beats Candel Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Tilray Brands?

Tilray Brands (NASDAQ:TLRY) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Tilray Brands presently has a consensus price target of $11.50, suggesting a potential upside of 150.54%. Corbus Pharmaceuticals has a consensus price target of $40.67, suggesting a potential upside of 397.15%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Tilray Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tilray Brands	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Corbus Pharmaceuticals has a net margin of 0.00% compared to Tilray Brands' net margin of -156.51%. Tilray Brands' return on equity of -3.31% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tilray Brands	-156.51%	-3.31%	-2.42%
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%

Corbus Pharmaceuticals has lower revenue, but higher earnings than Tilray Brands. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tilray Brands	$821.31M	0.65	-$2.19B	-$13.65	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A

In the previous week, Tilray Brands had 14 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 20 mentions for Tilray Brands and 6 mentions for Corbus Pharmaceuticals. Tilray Brands' average media sentiment score of 0.68 beat Corbus Pharmaceuticals' score of -0.10 indicating that Tilray Brands is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tilray Brands	9 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corbus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tilray Brands has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.57, indicating that its stock price is 157% more volatile than the broader market.

9.4% of Tilray Brands shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 0.8% of Tilray Brands shares are owned by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Corbus Pharmaceuticals beats Tilray Brands on 10 of the 16 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Gyre Therapeutics?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Corbus Pharmaceuticals presently has a consensus target price of $40.67, indicating a potential upside of 397.15%. Gyre Therapeutics has a consensus target price of $17.00, indicating a potential upside of 162.35%. Given Corbus Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Corbus Pharmaceuticals is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Corbus Pharmaceuticals has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Corbus Pharmaceuticals has a beta of 2.57, suggesting that its share price is 157% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Gyre Therapeutics has higher revenue and earnings than Corbus Pharmaceuticals. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Gyre Therapeutics	$116.59M	5.39	$5.03M	-$0.09	N/A

In the previous week, Corbus Pharmaceuticals had 6 more articles in the media than Gyre Therapeutics. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 0 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.00 beat Corbus Pharmaceuticals' score of -0.10 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Neutral
Gyre Therapeutics	Neutral

Summary

Corbus Pharmaceuticals beats Gyre Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Bright Minds Biosciences?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Bright Minds Biosciences (NASDAQ:DRUG) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.

In the previous week, Corbus Pharmaceuticals had 6 more articles in the media than Bright Minds Biosciences. MarketBeat recorded 6 mentions for Corbus Pharmaceuticals and 0 mentions for Bright Minds Biosciences. Bright Minds Biosciences' average media sentiment score of 0.00 beat Corbus Pharmaceuticals' score of -0.10 indicating that Bright Minds Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Neutral
Bright Minds Biosciences	Neutral

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.5% of Bright Minds Biosciences shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Comparatively, 42.7% of Bright Minds Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Bright Minds Biosciences' return on equity of -20.58% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-70.89%	-61.78%
Bright Minds Biosciences	N/A	-20.58%	-20.25%

Corbus Pharmaceuticals currently has a consensus price target of $40.67, indicating a potential upside of 397.15%. Bright Minds Biosciences has a consensus price target of $143.83, indicating a potential upside of 117.21%. Given Corbus Pharmaceuticals' higher probable upside, research analysts plainly believe Corbus Pharmaceuticals is more favorable than Bright Minds Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Bright Minds Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Bright Minds Biosciences is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$5.82	N/A
Bright Minds Biosciences	N/A	N/A	-$8.74M	-$2.44	N/A

Corbus Pharmaceuticals has a beta of 2.57, indicating that its share price is 157% more volatile than the broader market. Comparatively, Bright Minds Biosciences has a beta of -5.53, indicating that its share price is 653% less volatile than the broader market.

Summary

Corbus Pharmaceuticals and Bright Minds Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

Get Corbus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBP vs. The Competition

Export

Metric	Corbus Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$156.74M	$2.99B	$6.74B	$12.32B
Dividend Yield	N/A	1.78%	2.68%	5.88%
P/E Ratio	-1.41	18.65	25.13	23.95
Price / Sales	N/A	341.96	540.80	107.90
Price / Cash	N/A	56.64	45.29	53.76
Price / Book	0.97	4.14	10.67	6.41
Net Income	-$78.54M	$64.45M	$3.56B	$337.14M
7 Day Performance	-0.97%	1.22%	0.96%	-1.07%
1 Month Performance	-27.93%	0.95%	0.77%	0.48%
1 Year Performance	-5.65%	25.22%	30.23%	28.42%

Corbus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBP Corbus Pharmaceuticals	3.7566 of 5 stars	$8.18 -3.3%	$40.67 +397.1%	+2.8%	$156.74M	N/A	N/A	40	Analyst Forecast
ACRS Aclaris Therapeutics	3.0507 of 5 stars	$4.32 -1.0%	$11.50 +166.5%	+215.1%	$604.03M	$7.83M	N/A	100
CADL Candel Therapeutics	2.0165 of 5 stars	$8.05 -6.0%	$18.00 +123.6%	+91.1%	$595.76M	N/A	N/A	60	News Coverage
TLRY Tilray Brands	3.7142 of 5 stars	$4.91 -1.9%	$11.50 +134.1%	+20.2%	$569.35M	$821.31M	N/A	2,842
GYRE Gyre Therapeutics	2.071 of 5 stars	$5.86 -0.1%	$17.00 +190.3%	-14.8%	$568.60M	$116.59M	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBP) was last updated on 6/25/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. ACRS, CADL, TLRY, GYRE, and DRUG

How does Corbus Pharmaceuticals compare to Aclaris Therapeutics?

Summary

How does Corbus Pharmaceuticals compare to Candel Therapeutics?

Summary

How does Corbus Pharmaceuticals compare to Tilray Brands?

Summary

How does Corbus Pharmaceuticals compare to Gyre Therapeutics?

Summary

How does Corbus Pharmaceuticals compare to Bright Minds Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. ACRS, CADL, TLRY, GYRE, and DRUG

How does Corbus Pharmaceuticals compare to Aclaris Therapeutics?

Do insiders and institutionals hold more shares of ACRS or CRBP?

Is ACRS or CRBP more profitable?

Do analysts rate ACRS or CRBP?

Which has preferable valuation & earnings, ACRS or CRBP?

Does the media prefer ACRS or CRBP?

Which has more risk and volatility, ACRS or CRBP?

Summary

How does Corbus Pharmaceuticals compare to Candel Therapeutics?

Which has more volatility and risk, CRBP or CADL?

Is CRBP or CADL more profitable?

Do insiders & institutionals have more ownership in CRBP or CADL?

Do analysts rate CRBP or CADL?

Which has preferable earnings and valuation, CRBP or CADL?

Does the media favor CRBP or CADL?

Summary

How does Corbus Pharmaceuticals compare to Tilray Brands?

Do analysts prefer TLRY or CRBP?

Is TLRY or CRBP more profitable?

Which has better valuation & earnings, TLRY or CRBP?

Does the media refer more to TLRY or CRBP?

Which has more volatility and risk, TLRY or CRBP?

Do institutionals and insiders hold more shares of TLRY or CRBP?

Summary

How does Corbus Pharmaceuticals compare to Gyre Therapeutics?

Do analysts rate CRBP or GYRE?

Is CRBP or GYRE more profitable?

Which has more volatility and risk, CRBP or GYRE?

Do insiders & institutionals believe in CRBP or GYRE?

Which has better valuation and earnings, CRBP or GYRE?

Does the media refer more to CRBP or GYRE?

Summary

How does Corbus Pharmaceuticals compare to Bright Minds Biosciences?

Does the media favor CRBP or DRUG?

Do institutionals and insiders have more ownership in CRBP or DRUG?

Is CRBP or DRUG more profitable?

Do analysts recommend CRBP or DRUG?

Which has stronger earnings & valuation, CRBP or DRUG?

Which has more risk & volatility, CRBP or DRUG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools